A Phase 2 interventional study of Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified in Purpura, Thrombocytopenic, Idiopathic, sponsored by Grifols Therapeutics LLC. Completed at 1 site in United States. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-04-27.
Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic — 3 open to participants now, 3 under way, 1 of them phase 3. Immunoglobulins, Intravenous · Purpura, Thrombocytopenic, Idiopathic.
Among the 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic, this one is the 13th largest by enrollment, is one of 2 that started in 2003, is one of 3 in phase 2, and was the 3rd registered.
505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →3 of the 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic are open now, in 9 countries. Recruiting first, the newest first:
Kedrion S.p.A. · Sites in United States, Czechia, Germany and 5 more countries
Ages 18–70
Peking University People's Hospital · Sites in China
Ages 18–50 · Women only
Fujian Medical University Union Hospital · Sites in China
Ages 29 days–14 yrs
By country, each count listing its studies:
Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 58 across 378 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 40 across the 13 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 13 have an industry lead sponsor. The 10 most frequent:
This study is registered under Grifols Therapeutics LLC, one of the names counted as Grifols. Under that name alone:
Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
Grifols has 3 studies filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
1 of the studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059000Phase 3Kedrion S.p.A.A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to determine if the safety and tolerability of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatograph Purified (IGIV-C) is similar when infused at two different infusion rates.
This is a prospective, randomized, single-center, open, cross-over trial in patients with a confirmed diagnosis of Idiopathic Thrombocytopenia Purpura (ITP). ITP is defined as isolated thrombocytopenia in a patient with no other clinically apparent associated conditions or factors that are known to cause thrombocytopenia as defined by the ITP Practice Guidelines Committee of the American Society of Hematology.
Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) at a dose of 1.0 g/kg will be given on 2 occasions as a single daily infusion for platelet counts \< 30,000 microliters (uL) or if clinically indicated, at maximum intervals of six weeks. Eligible patients will be randomized into one of two cross-over groups. Patients randomized to Group 1 will receive their first IGIV-C infusion at a rate of 0.08 mL/kg/min and their second infusion at a rate of 0.14 mL/kg/min. Conversely patients randomized to Group 2 will receive their first IGIV-C infusion at a rate of 0.14 mL/kg/min and their second infusion at a rate of 0.08 mL/kg/min according to the following schema:
Group 1:
Group 2:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Infusion #1 (Week 0) IGIV-C (0.08 mL/kg/min); Infusion #2 (Week \<6) IGIV-C (0.14 mL/kg/min)
Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
Infusion #1 (Week 0) IGIV-C (0.14 mL/kg/min); Infusion #2 (Week \<6) IGIV-C (0.08 mL/kg/min)
Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
Drug page: Immunoglobulins, Intravenous
IGIV-C 10% at a dose of 1.0g/kg was to be given on 2 occasions as a single daily infusion: Group 1 were to receive their first IGIV-C, 10-% infusion at a rate of 0.08 mL/kg/min and a second infusion at 0.14 mL/kg/min. and Group 2 were to receive their first IGIV-C, 10-% infusion at a rate of 0.14 mL/kg/min and a second infusion at a rate of 0.08 mL/kg/min.
Also known as: Gamunex®, IGIVnex®, Gaminex, IGIV-C, IGIV-C, 10%, IVIG, BAY 41-1000, TAL-05-00004, Immune Globulin (Human), 10% (IGIV), Immune Globulin Intravenous, 10% by Chromatography Process, NDC 13533-645-12, NDC 13533-645-15, NDC 13533-645-20, NDC 13533-645-24, NDC 13533-645-71
Free Hemoglobin
Free hemoglobin as a measure to assess hemolysis.
Time frame: 24 hours after treatment
Hematocrit
Hematocrit as a measure to assess hemolysis
Time frame: 24 hrs after treatment
Red Blood Cells
Red blood cells as a measure to assess hemolysis
Time frame: 24 hrs after treatment
Change From Baseline in Platelet Levels
Time frame: 24 hours Post infusion and Day 7
Number of Subjects With Infusion Related Adverse Events
Time frame: 48 hours after treatment
Single-center, open label study in patients with a confirmed diagnosis of Idiopathic Thrombocytopenic Purpura (ITP).
| Milestone | IGIV-C, 10% - 0.08/0.14 mL/kg/Min | IGIV-C, 10% - 0.14/0.08 mL/kg/Min |
|---|---|---|
| Started | 4 | 4 |
| Completed | 4 | 4 |
| Not completed | 0 | 0 |
| Milestone | IGIV-C, 10% - 0.08/0.14 mL/kg/Min | IGIV-C, 10% - 0.14/0.08 mL/kg/Min |
|---|---|---|
| Started | 4 | 4 |
| Completed | 3 | 4 |
| Not completed | 1 | 0 |
| Withdrew: Pt did not meet study requirement | 1 | 0 |
Free hemoglobin as a measure to assess hemolysis.
| g/dL | IGIV-C, 10% (0.08 mL/kg/Min) | IGIV-C, 10% (0.14 mL/kg/Min) |
|---|---|---|
| Free Hemoglobin | 13.057 ± 1.778 | 12.371 ± 2.644 |
| participants | IGIV-C, 10% (0.08 mL/kg/Min) | IGIV-C, 10% (0.14 mL/kg/Min) |
|---|---|---|
| Number of Subjects With Infusion Related Adverse Events | 2 | 3 |
Hematocrit as a measure to assess hemolysis
| percentage of blood | IGIV-C, 10% (0.08 mL/kg/Min) | IGIV-C, 10% (0.14 mL/kg/Min) |
|---|---|---|
| Hematocrit | 36.80 ± 4.711 | 35.043 ± 6.793 |
Red blood cells as a measure to assess hemolysis
| 10^12 cells/L | IGIV-C, 10% (0.08 mL/kg/Min) | IGIV-C, 10% (0.14 mL/kg/Min) |
|---|---|---|
| Red Blood Cells | 4.1514 ± .4820 | 4.0786 ± 0.8258 |
| Giga/L | IGIV-C, 10% (0.08 mL/kg/Min) | IGIV-C, 10% (0.14 mL/kg/Min) |
|---|---|---|
| Baseline | 29.50 ± 28.47 | 6.86 ± 3.39 |
| 24 hours post infusion | 21.17 ± 35.49 | 42.29 ± 12.41 |
| Day 7 | 76 ± 138.35 | 118.7 ± 165.80 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IGIV-C, 10% - 0.08 mL/kg/Min | — | 0/8 (0%) | 8/8 (100%) |
| IGIV-C, 10% - 0.14 mL/kg/Min | — | 0/7 (0%) | 7/7 (100%) |
| Event | IGIV-C, 10% - 0.08 mL/kg/Min | IGIV-C, 10% - 0.14 mL/kg/Min |
|---|---|---|
| HeadacheNervous system disorders | 5/8 | 4/7 |
| UrticariaSkin and subcutaneous tissue disorders | 2/8 | 2/7 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/8 | 1/7 |
| RashSkin and subcutaneous tissue disorders | 2/8 | 1/7 |
| DizzinessNervous system disorders | 0/8 | 1/7 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 1/8 | 1/7 |
| Abdominal DistentionGastrointestinal disorders | 1/8 | 0/7 |
| DiarrhoeaGastrointestinal disorders | 1/8 | 0/7 |
| Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders | 1/8 | 0/7 |
| Age, Categorical(Participants) | IGIV-C, 10% - 0.08/0.14 mL/kg/Min | IGIV-C, 10% - 0.14/0.08 mL/kg/Min | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 4 | 7 |
| >=65 years | 1 | 0 | 1 |
| Age, Continuous(years) | IGIV-C, 10% - 0.08/0.14 mL/kg/Min | IGIV-C, 10% - 0.14/0.08 mL/kg/Min | Total |
|---|---|---|---|
| Mean | 47.75 ± 15.78 | 47.50 ± 14.89 | 47.63 ± 14.20 |
| Sex: Female, Male(Participants) | IGIV-C, 10% - 0.08/0.14 mL/kg/Min | IGIV-C, 10% - 0.14/0.08 mL/kg/Min | Total |
|---|---|---|---|
| Female | 3 | 4 | 7 |
| Male | 1 | 0 | 1 |
| Region of Enrollment(participants) | IGIV-C, 10% - 0.08/0.14 mL/kg/Min | IGIV-C, 10% - 0.14/0.08 mL/kg/Min | Total |
|---|---|---|---|
| United States | 4 | 4 | 8 |
The record gives a start of Jul 2003, a primary completion of Oct 2003 and a completion of Oct 2003. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 10 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous
Purpura, Thrombocytopenic, Idiopathic →